Benjamin Garmezy

Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis

Stephen J. Simko, Benjamin Garmezy, Harshal Abhyankar et al. · The Journal of Pediatrics · 2014 · 102 citations

Medicine, Dermatology, Pathology +12

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Toni K. Choueiri, Laurence Albigès, Philippe Barthélémy et al. · The Lancet · 2024 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Sreenivasa R Chandana, Noura J. Choudhury, Afshin Dowlati et al. · Journal of Clinical Oncology · 2024 · 30 citations

Medicine, Oncology, Pharmacology +17

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes

Andrew Leonard Laccetti, Benjamin Garmezy, Lianchun Xiao et al. · Cancer Medicine · 2021 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy, Mitesh J. Borad, Rastilav Bahleda et al. · Cancer Research Communications · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacology +15